**FAMILIAL HYPERCHOLESTEROLEMIA**

**Amy E. Levenson, MD,** Associate Professor of Pediatrics, Division of Pediatric Endocrinology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States. amy.levenson@unc.edu

**Sarah D. de Ferranti, MD, MPH,** Associate Professor of Pediatrics, Director of the Preventive Cardiology Clinic and Division Chief, Outpatient Cardiology, Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States. sarah.deferranti@cardio.chboston.org

**Updated November 28, 2023**

**ABSTRACT**

Familial hypercholesterolemia (FH) is a prevalent, autosomal co-dominant disorder of lipid metabolism that results in elevated low-density lipoprotein cholesterol (LDL-C) levels and premature atherosclerosis. Screening for and identifying heterozygous FH in childhood is critical, given its high prevalence and asymptomatic presentation. Furthermore, treatment of FH in childhood is effective at lowering LDL-C levels and has the potential to reduce atherosclerotic cardiovascular disease (ASCVD) events in adulthood. Selective screening based on family history had previously been recommended to identify children and adolescents with FH or other lipid disorders. However, studies indicated that many individuals with heterozygous FH were missed with this approach, and therefore in 2011 the National Heart, Lung, and Blood Institute Expert Panel recommended universal screening of children and adolescents between ages 9 and 11 years and again at ages 17 to 21 years, in addition to selective screening, in order to identify pediatric individuals with heterozygous FH. This approach was affirmed in the 2018 American College of Cardiology and the American Heart Association (ACC/AHA) Cholesterol Guidelines, along with endorsing cascade screening as another reasonable approach to identifying children with FH. Once FH is diagnosed, prompt treatment with lifestyle modification should be initiated. When lifestyle interventions are not sufficient, pharmacotherapy using statins has been shown to be effective at lowering LDL-C, generally safe in short and medium- term studies, and may be beneficial at reducing ASCVD events. Other medications can be useful at lowering LDL-C in conjunction with statin therapy, although generally statins are sufficient in young patients. Homozygous FH is a rare disorder manifesting as extremely high LDL-C and ASCVD in childhood, requiring aggressive multimodal management. Overall, studies are needed to determine the optimal timing and intensity of statin therapy, and to better understand long-term safety and ASCVD outcomes in adulthood for lipid-lowering pharmacotherapy initiated in pediatric patients with heterozygous FH.

**INTRODUCTION**

Familial hypercholesterolemia (FH), as classically described, is the most common single gene disorder of lipoprotein metabolism and causes severely elevated low-density lipoprotein cholesterol (LDL-C) levels. The prevalence of FH is 1 in 200 to 1 in 300 individuals of different ethnicities (1,2), and it is strongly associated with premature coronary artery disease (CAD) (3). Data from observational studies suggest that untreated FH is associated with ~90-fold increase in mortality due to atherosclerotic cardiovascular disease (ASCVD) in young adults (4). Since early treatment may significantly reduce CAD-related morbidity and mortality in individuals with heterozygous FH (5), early identification and intervention during childhood may greatly improve outcomes in adulthood.

**EPIDEMIOLOGY**

The prevalence of FH varies substantially, depending upon the criteria used to define the disorder and the ancestry of the population.  Previously, the prevalence had been described as 1 in 500 individuals based on early work by Drs. Brown and Goldstein (6,7).  More recent analysis of white European populations, which tend to be less ethnically and racially diverse than the US, show higher prevalence rates (8,9).  An analysis using a modified version of the Dutch Lipid Clinic (DLC) criteria applied to participants in the 1999 to 2012 National Health and Education National Surveys (NHANES), a nationally representative survey of the US population, suggest FH affects 1 in 250 US adults (1). The prevalence of FH in US children and adolescents is not as well characterized, although presumably it is similar. Some estimate that as few as 10% of individuals with FH have been identified in the US.

**PATHOPHYSIOLOGY AND GENETICS**

FH was initially defined by Brown and Goldstein as a disorder or defect in the LDL receptor (LDL-R) (3). More recently, the description of FH has been expanded and used to describe any defects in LDL-C processing and/or signaling that may lead to a phenotype characteristic of FH (10). FH may be more common and complicated than previously thought, with many different genetic variants leading to pathogenesis. Overall, nine genes are causative for autosomal forms of FH, and up to 50 polymorphic loci contribute to polygenic susceptibility to elevated LDL- cholesterol levels (11).  Some etiologies for the FH phenotype include defects in apoB100 lipoprotein, the major atherogenic lipoprotein component of LDL-C, as well as gain of function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9), which promotes the degradation of the LDLR, resulting in reduced LDL-C clearance (7). Gene mutations in LDL-R, the apolipoprotein B gene, or in PCSK9 occur in approximately 93, 5, and 2 percent of individuals with a phenotype consistent with FH, respectively (12). The associated impairment in function of these receptors or proteins results in overall reduced clearance of LDL particles from the circulation and elevation in plasma LDL-C. There is also increased uptake of modified LDL by macrophage scavenger receptors, resulting in lipid accumulation in macrophages and foam cell formation, a precursor to atherosclerotic plaque development (13). Thus, the typical lipid profile of FH is characterized by elevated LDL-C (as high as 300 mg/dL) with subsequently increased total cholesterol (TC) levels; in general, triglycerides are normal, and high-density lipoprotein (HDL-C) can be low or normal. FH has an autosomal dominant inheritance pattern which results in hypercholesterolemia and early ASCVD events.

There are various genetic mutations that can cause FH, which can either be monogenic or polygenic in nature. See Table 1 below for a list of genes that are associated with FH.

|  |
| --- |
| **Table 1. Genes Associated with FH** |
| **Monogenic** |
| Autosomal Dominant  LDLR  APOB  PCSK9  APOE\* |
| Autosomal Recessive  LDLRAP1  LIPA (Lysosomal acid lipase deficiency\*\*)  ABCG5 and ABCG8 (Sitosterolemia\*\*) |
| **Polygenic** |
| Genetic variants associated with FH which together can impact LDL-C levels |

\*Specific mutations or candidate regions associated with FH

\*\*Refer to specific Endotext sections on lysosomal acid lipase deficiency and sitosterolemia for more information

In general, homozygotes for mutations in the LDL-R gene are more adversely affected than heterozygotes, reflecting a “gene dosing effect” of inheritance.  Unless there is consanguinity in a family in which heterozygous FH is present, homozygous FH is less prevalent and may affect as many as 1 in 160,000–300,000 individuals (14).  Additionally, the homozygous FH phenotype can be seen in compound heterozygotes which can occur in offspring of unrelated parents due to a different disease-causing mutation on each allele. The severity of the FH phenotype does not necessarily depend upon the presence of true homozygosity or compound heterozygosity inheritance; rather it is determined by the degree of disturbance in LDL metabolism.  For additional information on the genetics as well as pathophysiology, refer to “Familial Hypercholesterolemia: Genes and Beyond” by Warden *et al*., [www.endotext.org](http://www.endotext.org) (15).

**FH PHENOTYPE**

**Clinical Symptoms**

HOMOZYGOUS FH

Due to the excessively high plasma LDL-C levels in homozygous FH, cholesterol deposits are common in the tendons (xanthomas) and eyelids (xanthelasmas), and generally appear by one year of age. Tendon xanthomata are most common in the Achilles tendons and dorsum of the hands but can occur at other sites. Tuberous xanthomata typically occur over extensor surfaces such as the knee and elbow.  Planar xanthomas may occur on the palms of the hands and soles of the feet and are often painful.  Xanthelasmas are cholesterol-filled, soft, yellow plaques that usually appear on the medial aspects of the eyelids. Corneal arcus is a white or grey ring around the cornea (16).

HETEROZYGOUS FH

In addition to increased serum cholesterol and risk for premature coronary artery disease (see below), patients with heterozygous FH may have tendon xanthomas and corneal arcus that appear after the age of 20 years (16).

**LDL-C Levels**

In clinical practice, there is not a universal LDL-C threshold that determines a diagnosis of FH. Generally, the level of LDL-C that warrants further evaluation depends upon the age of the patient and whether additional family members have known hypercholesterolemia and/or early ASCVD. As suggested by recent guidelines (7,17), children and adolescents with a negative or unknown family history and LDL-C level persistently ≥190 mg/dL (4.9 mmol/L) suggests FH; in patients with a positive family history of hypercholesterolemia or early ASCVD, an LDL-C level of ≥160 mg/dL(4.1 mmol/L) is consistent with FH (see Table 2).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 2. Acceptable, Borderline, and High Lipid Levels for Children and Adolescents** | | | | |
| **Lipid** | **Low (mg/dl)** | **Acceptable (mg/dl** | **Borderline-High (mg/dl)** | **High (mg/dl)** |
| TC |  | <170 | 170-199 | >200 |
| LDL-C |  | <110 | 110-129 | >130 |
| Non-HDL-C |  | <120 | 120-144 | >145 |
| Triglycerides  0-9 years  10-19 years |  | <75  <90 | 75-99  90-129 | >100  >130 |
| HDL-C | < 40 | >45 |  |  |

Adapted from the NCEP expert panel on cholesterol levels in children (14)

**Cardiovascular Disease**

Cardiovascular risk in FH patients is determined by both the LDL-C concentration and by other traditional risk factors. Homozygotes have early-onset atherosclerosis, including myocardial infarction, in the first decade of life (reported as early as age two years), and are at increased risk for CAD-related mortality in the first and second decades (16).  Additionally, patients with homozygous FH can develop cholesterol and calcium deposits that can lead to aortic stenosis and occasionally to mitral regurgitation.

Heterozygotes are also at increased risk for early-onset CAD between the ages of 30-60 years (18). Children with heterozygous FH have thicker carotid intima-media thickness (cIMT), an anatomic measure of arterial thickness associated with atherosclerosis, compared to unaffected siblings and healthy controls (19,20). One study showed those treated with statin medications (HMG-CoA reductase inhibitors) at younger ages had less carotid atherosclerosis compared to the placebo group. Results from long-term studies of statins in children with FH are just emerging, and indicate that statin treatment during childhood may slow progression of cIMT and reduce the risk of CVD in adulthood (21).

**SCREENING**

Given the high prevalence of FH and the improved outcomes with early treatment, pediatric lipid screening has become very important for the detection of FH. However, the approach to lipid screening in childhood and adolescences has varied over the past decades and is somewhat controversial, with the US Preventative Services Task Force (USPSTF) recently concluding that that the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents (22). Selective screening of young individuals with a family history of hypercholesterolemia and/or early CV events or patients at risk for atherosclerosis for other medical conditions has been recommended for several decades (23–25). However, screening individuals based only on family history may miss 30-50% of children with elevated LDL (24–26). Thus, the 2011 Expert Panel, supported by the more recent 2018 ACC/AHA Cholesterol Guidelines (27), recommended universal lipid screening, which involves screening in childhood at two time points, once between ages 9 and 11 years, and then again between ages 17 and 21 years (28). Universal screening is recommended in those not already selectively screened based on family history or personal risk factors (Table 3).

Selective screening for FH involves obtaining a fasting or non-fasting lipid panel in individuals ages 2 to 21 years with:

1. Family history of early atherosclerosis or high cholesterol.
2. Relatives of individuals with identified FH.

Lipid testing should also be performed in the presence of risk factors or medical diagnoses that increase risk for CVD (including hypertension, current cigarette smoking, body mass index ≥ 85th percentile, diabetes mellitus type I and II, chronic kidney disease/end-stage renal disease, chronic inflammatory diseases, human immunodeficiency virus infection, and nephrotic syndrome) (28).

Universal screening involves obtaining either a fasting lipid profile or a non-fasting non-HDL, (calculated by subtracting HDL from TC) in childhood at two time points:

1. Between ages 9-11 years.
2. Between ages 17-21 years.

|  |  |  |
| --- | --- | --- |
| **Table 3. Screening for Hypercholesterolemia** | | |
| **Approach** | **Age in Years** | **Population** |
| Selective | 2-21 | Family history of early atherosclerosis or high cholesterol  Presence of risk factors or medical conditions that increased early CVD risk\* |
| Universal | 9-11 and 17-21 | All |

\*Selective screening is indicated in individuals with hypertension, current cigarette smoking, body mass index ≥ 85thpercentile, diabetes mellitus type I and II, chronic kidney disease/end-stage renal disease, chronic inflammatory diseases, human immunodeficiency virus infection, and nephrotic syndrome

**DIAGNOSIS**

The diagnosis of FH can be made clinically and through genetic testing; genotype needs to be interpreted in the context of phenotype. For heterozygous FH, the clinical diagnosis is made based on the presence of high levels of total and LDL cholesterol in combination with one or more of following (17):

1. Family history of hypercholesterolemia (especially in children) or known FH.
2. History of premature CAD in the patient or in family members.
3. Physical examination findings of abnormal deposition of cholesterol in extravascular tissues (e.g., tendon xanthoma), although these rarely occur in childhood.

There are several clinical scoring systems used to diagnose FH, and these vary based on the weight given for each diagnostic criteria (11).  In general, clinical diagnosis of homozygous FH can be made in individuals with the following criteria (14):

1. Untreated LDL-C >500mg/dL (>13 mmol/L) or treated LDL-C ≥300 mg/dL (>8 mmol/L), AND
2. Cutaneous or tendon xanthoma before age 10 years, OR
3. Elevated LDL-C levels consistent with heterozygous FH in both parents.

There are various disease states or other factors that can increase LDL-C levels and should be considered when diagnosing FH. Some of these include the following:

* Obesity
* Hypothyroidism
* Diabetes mellitus
* Nephrotic syndrome
* Chronic renal failure
* Cholestasis
* Biliary atresia
* Hepatitis
* Biliary cirrhosis
* HIV infection/AIDS
* Various drugs/medications
* Alcohol
* Pregnancy
* Very low carbohydrate ketogenic diets

**Genetic Testing**

Identifiable gene defects in LDLR, APOB, or PCSK9 have been identified in 60 to 80% of individuals with a heterozygote FH phenotype. Genetic testing has not routinely been performed in the clinical setting due to concerns about cost to the patient and because it was not likely to alter management, given that treatment decisions were usually based on LDL-C levels. However, FH genetic testing has recently been recommended to become the standard of care for patients with definite or probable FH, and the rationale for such testing includes the following: 1) facilitation of definitive diagnosis of FH lowers the concern for other secondary causes of high LDL-C; 2) pathogenic variants correlate with higher cardiovascular risk, which indicates the potential need for more aggressive lipid lowering; 3) increase in initiation of and adherence to therapy; and 4) cascade testing of at-risk relatives (29). Overall, the clinical significance of normal or moderately elevated LDL-C levels in the setting of a genetic defect in the LDLR or other possibly pathogenic defects is unknown.

**TREATMENT**

The guidelines for initiating treatment in patients with the FH phenotype are based on age, severity of LDL-C elevation, as well as family and medical histories. Lifestyle therapy is recommended for all children and adolescents with LDL-C levels ≥ 130 mg/dL. If lifestyle intervention is insufficient, medications can be considered in children beginning at age 10 years, or as early as age 8 in high-risk patients and in the presence of a very high-risk family history. For healthy children and adolescents ages 10-21 years, lifestyle therapy should be provided to those with an LDL-C ≥ 130 mg/dL, and medication should be initiated if LDL-C remains ≥ 190 mg/dL despite 6 or more months of lifestyle modification. If there is a family history of early atherosclerotic disease, then medication should be started in individuals with LDL-C levels ≥ 160 mg/dL who do not respond sufficiently to lifestyle modification. If an individual has a high-risk medical condition, as noted above, medication can be considered for those with a persistently elevated LDL-C ≥ 130 mg/dL. In general, the goal of treatment is to maintain an LDL-C level ≤ 130 mg/dL or ≥ 50% reduction in LDL concentration; lower ranges may be considered in high-risk patients. Medications should be initiated in all patients with homozygous FH at the time of diagnosis, regardless of age, and additional treatments should also be considered.

**Lifestyle Treatment**

The mainstay of treatment for pediatric lipid disorders is lifestyle modification. A low saturated fat diet, without trans-fat, and high in fruits and vegetables, is the recommended diet for lowering LDL-C. This dietary approach has been shown to be both safe and beneficial in the general pediatric population (28,30,31).  Additionally, nutritional and physical activity interventions have been shown to lower LDL-C and improve CVD risk factors in children with obesity in meta-analyses (32). Despite this, in adults with FH, lifestyle modifications have been shown to only lower LDL-C modestly (33).  Furthermore, the effect of physical activity on LDL-C levels has not been well studied in children with FH.

**Pharmacotherapy**

STATINS

The majority of patients with FH are treated with medications, and statins are the recommended first line pharmacotherapy. In a Cochrane meta-analysis of pediatric patients with FH, statins were shown to lower LDL-C by 32% (34). Furthermore, more intensive statin therapy in high doses has been shown to lower LDL-C even more significantly, by up to 50% (35,36). Follow-up data from a statin trial in pediatric Dutch patients suggest efficacy and safety, as well as decreased atherosclerosis compared to the subjects’ parents (37). Most recently, the use of statins in children with FH have shown reduced CVD risk in adulthood for these patients compared to their untreated parents with FH, after a 20 year follow-up (21). Although this study was not a controlled or placebo study, it suggests that long-term statin use in childhood may prevent ASCVD compared to not treating.

Several different formulations of statin therapy are available and approved by the US Food and Drug Administration (FDA) for use in children. Treatment is initiated at a low dose (generally 5-20mg depending on the statin potency), which is given once a day, often at night. If needed, the dose is increased to meet the goals of therapy. Side effects with statins are rare, but include myopathy, new-onset type 2 diabetes mellitus (reported in adult primary prevention statin trials), and hepatic enzyme elevation. In pediatric clinical trials, rates of side effects with statin therapy were low and adherence to statin therapy was generally good (38). Side effects of statins are more likely at higher doses and in patients taking other medications, particularly [cyclosporine](http://www.uptodate.com/contents/cyclosporine-pediatric-drug-information?source=see_link), azole antifungal agents, and other medications and foods (such as grapefruit) that impact the cytochrome P450 system. Adolescent females should be counseled about the possibility of drug teratogenicity and appropriate contraceptive methods while receiving statin therapy. Additionally, providers should be aware that oral contraceptive pills can increase lipid levels.

The NHLBI guidelines recommend the following baseline laboratory evaluation when initiating statin therapy (28):

* Fasting lipid profile.
* Serum creatine kinase (CK).
* Hepatic enzymes (i.e., serum alanine aminotransferase [ALT] and aspartate aminotransferase [AST]).

Screening for type 2 diabetes is also reasonable prior to starting statins. Fasting lipid profiles are repeated at four weeks after the initiation of statin therapy to titrate dose and are repeated every six months in patients on stable therapy. Liver function tests, CK, and hemoglobin A1C should be obtained if signs of adverse effects arise, and may be obtained at regular intervals, for example after dose changes based on best clinical judgement. Ongoing monitoring of growth, other measures of general and cardiovascular health, and review for the presence of additional ASCVD risk factors, such as smoking exposure, should also occur at each visit.

BILE ACID BINDING RESINS

Although bile acid binding resins or bile acid sequestrants have been shown to lower LDL-C by ~10-20% in pediatric trials (39,40), they are often difficult to tolerate given their unpalatability and associated adverse effects (such as bloating and constipation) (41). For these reasons, bile acid binding resins are used relatively infrequently. However, they may be useful in combination with a statin for patients who fail to meet target LDL-C levels (42). The sequestrants are not absorbed systemically, remain in the intestines, and are excreted along with bile containing cholesterol. Therefore, they are considered to be very safe. They can be used in patients who prefer to avoid statins, although they may not lower LDL-C sufficiently to achieve goal levels.

CHOLESTEROL ABSORPTION INHIBITORS (EZETIMIBE)

Ezetimibe is a lipid-lowering mediation that inhibits absorption of cholesterol and plant sterols in the intestines. This agent can be useful in pediatric patients with FH who are not able to reach LDL-C treatment goals on high-intensity statin therapy. Ezetimibe further lowers serum LDL-C and in adults has been shown to improve cardiovascular outcomes without altering the side effect profile (43–45). Specifically in the pediatric population, ezetimibe has been shown to be safe and effective at lowering LDL-C by up to almost 30%, even when used as monotherapy (44,46,47)

PCSK9 INHIBITORS

PCSK9 inhibitors ([evolocumab](http://www.uptodate.com/contents/evolocumab-drug-information?source=see_link) and [alirocumab](http://www.uptodate.com/contents/alirocumab-drug-information?source=see_link)) are human monoclonal antibodies that bind to PCSK9 and promote plasma LDL cholesterol clearance. In Europe, evolocumab is approved in adolescents (≥12 years old) with homozygous FH. In the US, alirocumab is approved only for use in adult patients, and evolocumab is approved for use in adults with heterozygous FH and in homozygous FH, ages 13 and older, who have not responded to other LDL-C lowering therapies. Overall, PCSK9 inhibitors appear to have a good safety and side effect profile in adults (48). These medications have been shown to be very effective, reducing LDL-C by more than 15% in patients with homozygous FH and by 35% in patients with heterozygous FH (49–51). The main disadvantage of PCSK9 inhibitors is that they require injection for administration; cost is also a concern.

Inclisiran is another medical therapy that targets PCSK9 synthesis through a different mechanism. It is a small interfering RNA molecule that triggers the breakdown of messenger RNA coding for the PCSK9 protein. This medication has been recently approved for clinical use and has been shown to be safe and effective in adult patients with heterozygous FH (49). Clinical trials of inclisiran are currently underway in adolescent patients with heterozygous and homozygous FH (50).

EMERGING MEDICAL THERAPIES

There are several promising therapies that aim to reduce LDL-C through different approaches. These include Bempedoic Acid, Lomitapide, and Evinacumab. Bempedoic acid blocks the cholesterol biosynthetic pathway upstream of HMG-CoA reductase through inhibition of adenosine triphosphate citrate lyase. This therapeutic agent has been shown to be effective in treating statin-resistant hypercholesterolemia and in reducing ASCVD in adults (51,52). Bempedoic acid is currently being studied in children with heterozygous FH.

Microsomal triglyceride transfer protein (MTP) plays an essential role in the formation of apoB-containing lipoproteins and has been shown to be inhibited by Lomitapide (53). This drug can reduce LDL-C by approximately 58% and has been approved for use in adults with homozygous FH. So far, Lomitapide has been observed to be safe and effective in pediatric patients with homozygous FH (54).

Evinacumab is a human monoclonal antibody that targets angiopoietin-like 3 (ANGPTL3), which results in the reduction of LDL-C levels via an LDL-receptor independent mechanism (55–57). This drug has been shown to significantly reduce LDL-C in patients with homozygous FH who show little to no LDL-receptor activity and who have had poor response to other treatments (58). Additionally, patients with heterozygous FH have also shown improvements in LDL-C by 50% reduction (59). Evinacumab was approved in early 2021 by the FDA for the treatment of homozygous FH patients starting at age 12 years (60).

**Lipoprotein Apheresis**

Although statin therapy has been shown to be effective in reducing LDL and prolonging life expectancy in patients with homozygous FH (61), medical treatment alone may not be adequate to achieve recommended treatment goals. Therefore, it is suggested that lipoprotein apheresis (LA) be initiated in patients with homozygous FH as young as 2 years. The efficacy is dependent upon the type of apheresis but can reduce LDL-C by as much as 45 to 80%. Studies in pediatric patients are limited, but there is some evidence suggesting that LA therapy is safe and effective in children with homozygous FH (62).

**SUMMARY**

FH is an autosomal dominant disorder of LDL metabolism that affects 1 in 200 to 300 individuals. Screening involving lipid measurements, family and medical history, and physical examination is needed to identify affected individuals; cascade screening can be helpful. Lifestyle modification is the first-line therapy for hyperlipidemia in pediatric patients but is usually not sufficient to achieve goal LDL levels. Available evidence suggests that treatment with lipid-lowering pharmacotherapy, such as statins, is effective and generally safe in the short and medium-term.  However, further studies are needed to determine the long-term safety and efficacy in preventing ASCVD of lipid lowering medication in pediatric patients with FH.

**REFERENCES**

1. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation. 2016 Mar 15;133(11):1067-72.

2. Toft-Nielsen F, Emanuelsson F, Benn M. Familial Hypercholesterolemia Prevalence Among Ethnicities-Systematic Review and Meta-Analysis. Front Genet. 2022 Feb 3;13:840797.

3. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. *J Clin Invest Internet*. Published online July 1973. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=302426&tool=pmcentrez&rendertype=abstract

4. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. *Eur Heart J Internet*. Published online 2008. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2577142&tool=pmcentrez&rendertype=abstract

5. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. *BMJ Internet*. Published online 2008. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2583391&tool=pmcentrez&rendertype=abstract

6. Brown MS, Goldstein JL. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. *Sci Internet*. Published online July 5, 1974. http://www.ncbi.nlm.nih.gov/pubmed/4366052

7. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol Internet*. Published online 2011. http://www.ncbi.nlm.nih.gov/pubmed/21600525

8. Watts GF, Shaw JE, Pang J, Magliano DJ, Jennings GLR, Carrington MJ. Prevalence and treatment of familial hypercholesterolaemia in Australian communities. *Int J Cardiol Internet*. Published online April 15, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25791093

9. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. *Am J Epidemiol Internet*. Published online September 1, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15321838

10. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol Internet*. Published online 2011. http://www.ncbi.nlm.nih.gov/pubmed/21600530

11. Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. *Nat Rev Cardiol Internet*. 2019;16(1):9-20. doi:10.1038/s41569-018-0052-6

12. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. http://www.ncbi.nlm.nih.gov/pubmed/23433573

13. Epstein FH, Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond Cholesterol. *N Engl J Med Internet*. Published online 1989. http://www.ncbi.nlm.nih.gov/pubmed/2648148

14. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *Eur Heart J Internet*. Published online August 21, 2014. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4139706&tool=pmcentrez&rendertype=abstract

15. Warden BA, Fazio S, Shapiro MD, et al. Familial Hypercholesterolemia: Genes and Beyond. editors., ed. *Endotext Internet South Dartm MA MDTextcom Inc*. Published online 2018.

16. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. *Curr Opin Lipidol Internet*. Published online 2004. http://www.ncbi.nlm.nih.gov/pubmed/15243214

17. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J Internet*. Published online 2013. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3844152&tool=pmcentrez&rendertype=abstract

18. Ose L. Familial hypercholesterolemia from children to adults. http://www.ncbi.nlm.nih.gov/pubmed/12652097

19. Wiegman A, Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. *Internet*. Published online January 31, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15070569

20. Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. *Arter Thromb Vasc Biol Internet*. Published online 1996. http://www.ncbi.nlm.nih.gov/pubmed/8696963

21. Kusters DM, Ph D, Hof MH, Ph D. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. :2019 1547-56.

22. Association AM. Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia. *Evid Rep Syst Rev US Prev Serv Task Force*. 2019;98101(6):645-655.

23. Daniels G SR, F.R. Lipid screening and cardiovascular health in childhood. *Pediatr Internet*. Published online 2008. http://www.ncbi.nlm.nih.gov/pubmed/18596007

24. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III. *JAMA Internet*. Published online May 16, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11368702

25. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. *Pediatr Internet*. Published online 1992. http://www.ncbi.nlm.nih.gov/pubmed/1741227

26. Dennison BA, Jenkins PL, Pearson TA. Challenges to implementing the current pediatric cholesterol screening guidelines into practice. *Pediatr Internet*. Published online 1994. http://www.ncbi.nlm.nih.gov/pubmed/8065853

27. Grundy SM, Stone NJ, Bailey AL, Jones DW, Beam C, Lloyd-jones D. In: *AHA / ACC / AACVPR / AAPA / ABC / ACPM / ADA / AGS / APhA / ASPC / NLA / PCNA Guideline on the Management of Blood Cholesterol A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines WRIT*. ; 2018.

28. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatr Internet*. Published online 2011. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4536582&tool=pmcentrez&rendertype=abstract

29. Sturm AC, Knowles JW, Gidding SS, et al. Clinical Genetic Testing for Familial Hypercholesterolemia JACC Scienti fi c Expert Panel. *Lipid Screen Child*. 2019;1(10):1437-1438.

30. Niinikoski H, Lagström H, Jokinen E, Siltala M, Rönnemaa T, Viikari J. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. *Circ Internet*. Published online August 28, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17698729

31. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC). The Writing Group for the DISC Collaborative Research Group. *JAMA Internet*. Published online May 10, 1995. http://www.ncbi.nlm.nih.gov/pubmed/7723156

32. Ho M, Garnett SP, Baur L, Burrows T, Stewart L, Neve M. Effectiveness of lifestyle interventions in child obesity: systematic review with meta-analysis. *Pediatr Internet*. Published online 2012. http://www.ncbi.nlm.nih.gov/pubmed/23166346

33. Pt K, Se H. Statins for children with familial hypercholesterolemia (Review. Published online 2019.

34. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev Internet*. Published online 2014. http://www.ncbi.nlm.nih.gov/pubmed/25054950

35. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. *J Pediatr*. 2003;143(1):74-80. doi:10.1016/S0022-3476(03)00186-0

36. Avis HJ, Hutten BA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. *J Am Coll Cardiol*. 2010;55(11):1121-1126. doi:10.1016/j.jacc.2009.10.042

37. Kusters DM, Avis HJ, Groot E, Wijburg FA, Kastelein JJP, Wiegman A. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. *JAMA Internet*. Published online September 10, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25203086

38. Braamskamp MJAM, Kusters DM, Avis HJ, Smets EMA, Wijburg FA, Kastelein JJP. Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. *Paediatr Drugs Internet*. Published online 2015. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4372689&tool=pmcentrez&rendertype=abstract

39. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. *J Pediatr Internet*. Published online July 1996. http://www.ncbi.nlm.nih.gov/pubmed/8757561

40. Liacouras CA, Coates PM, Gallagher PR, Cortner JA. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia. *J Pediatr Internet*. Published online 1993. http://www.ncbi.nlm.nih.gov/pubmed/8441109

41. McCrindle BW, O’Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. *J Pediatr Internet*. Published online 1997. http://www.ncbi.nlm.nih.gov/pubmed/9042130

42. McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. http://www.ncbi.nlm.nih.gov/pubmed/12032266

43. Ip C, Jin D, Gao J, Meng Z, Meng J, Tan Z. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. *Int J Cardiol Internet*. Published online July 15, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25965621

44. Kusters DM, Caceres M, Coll M, Cuffie C, Gagné C, Jacobson MS. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. *J Pediatr Internet*. Published online 2015. http://www.ncbi.nlm.nih.gov/pubmed/25841542

45. van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, Veltri E, Avis HJ, Kastelein JJ. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008 Oct 21;52(17):1421-9

46. Yeste D, Chacón P, Clemente M, Albisu MA, Gussinyé M, Carrascosa A. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. *J Pediatr Endocrinol Metab JPEM*. 2009;22(6):487-492. doi:10.1515/jpem.2009.22.6.487

47. Clauss S, Wai KM, Kavey REW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. *J Pediatr*. 2009;154(6):869-872. doi:10.1016/j.jpeds.2008.12.044

48. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. *BMC Med Internet*. Published online 2015. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4477483&tool=pmcentrez&rendertype=abstract

49. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020;382(16):1520-1530. doi:10.1056/NEJMoa1913805

50. Reijman MD, Schweizer A, Peterson ALH, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. *Eur J Prev Cardiol*. 2022;29(9):1361-1368. doi:10.1093/eurjpc/zwac025

51. Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. *JAMA*. 2019;322(18):1780-1788. doi:10.1001/jama.2019.16585

52. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. *N Engl J Med*. 2023;388(15):1353-1364. doi:10.1056/NEJMoa2215024

53. Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. *Core Evid*. 2019;14:19-30. doi:10.2147/CE.S174169

54. Ben-Omran T, Masana L, Kolovou G, et al. Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. *Adv Ther*. 2019;36(7):1786-1811. doi:10.1007/s12325-019-00985-8

55. Adam RC, Mintah IJ, Alexa-Braun CA, et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. *J Lipid Res*. 2020;61(9):1271-1286. doi:10.1194/jlr.RA120000888

56. Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. *J Am Coll Cardiol*. 2017;69(16):2054-2063. doi:10.1016/j.jacc.2017.02.030

57. Rhee JW, Wu JC. Dyslipidaemia: In vivo genome editing of ANGPTL3: a therapy for atherosclerosis? *Nat Rev Cardiol*. 2018;15(5):259-260. doi:10.1038/nrcardio.2018.38

58. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020;383(8):711-720. doi:10.1056/NEJMoa2004215

59. Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in Patients with Refractory Hypercholesterolemia. *N Engl J Med*. 2020;383(24):2307-2319. doi:10.1056/NEJMoa2031049

60. Markham A. Evinacumab: First Approval. *Drugs*. 2021;81(9):1101-1105. doi:10.1007/s40265-021-01516-y

61. Raal FJ, Pilcher GJ, Panz VR, Deventer HE, Brice BC, Blom DJ. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. *Circulation*. 2011;124(20):2202-2207.

62. Luirink IK, Determeijer J, Hutten BA, Wiegman A, Bruckert E, Schmitt CP. Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review. *J Clin Lipidol*. 2019;13(1):31-39.